Actively Recruiting
Study of Itopride to Improve Gastroparesis Caused by Semaglutide in Women Having Elective Hysterectomy
Led by Ain Shams University · Updated on 2025-11-28
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the effect of Itopride on gastroparesis caused by Semaglutide, a medication used in type 2 diabetes and obesity treatment. Semaglutide delays gastric emptying and increases the risk of aspiration during anesthesia, which the study intends to address by testing if Itopride can improve gastric emptying and reduce residual stomach contents before surgery. Participants will be randomly assigned to receive either oral Itopride tablets or placebo tablets three times daily, one hour before meals, for seven days. The study is designed as a prospective, randomized, double-blind controlled trial focusing on women aged 40 to 60 years undergoing elective hysterectomy and using Semaglutide. During the study, researchers will use gastric ultrasound to assess residual gastric contents after eight hours of fasting on days 3, 5, and 7 before anesthesia. They will also monitor the incidence of vomiting during anesthesia. The trial includes safety monitoring and will last through the treatment period, with the primary measurement taken on day 7.
CONDITIONS
Brief Title
Effect of Itopride on Semaglutide Gastroparesis
Research Team
T
tamer Samir abdelaziz, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
